Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types 

Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment 

Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel 

Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody  

Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib 

Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor  

Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 

Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments 

CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies  

An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions